Locus Cell Co., Ltd.

Equities

6891

TW0006891005

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-06-27 pm EDT			5-day change	1st Jan Change
32.1 ^TWD	-1.23%		-1.38%	+1.90%

Jun. 26	Locus Cell Co., Ltd. Appoints Kun-Ying, Tsai as Chief Operating Officer, Effective July 15, 2024	CI
May. 24	Locus Cell Co., Ltd. Announces Board Changes	CI

Locus Cell Co., Ltd. Appoints Kun-Ying, Tsai as Chief Operating Officer, Effective July 15, 2024

June 26, 2024 at 06:29 am EDT

Locus Cell Co., Ltd. announced the board of directors has resolved to appoint a chief operating officer. Name, title, and resume of the new position holder: Mr. Kun-Ying, Tsai. Type of change: New replacement.

Effective date: July 15, 2024.

Latest news about Locus Cell Co., Ltd.

Locus Cell Co., Ltd. Appoints Kun-Ying, Tsai as Chief Operating Officer, Effective July 15, 2024	Jun. 26	CI
Locus Cell Co., Ltd. Announces Board Changes	May. 24	CI
Locus Cell Co., Ltd. Announces the Expiration of First Compensation Committee Members	May. 24	CI
Locus Cell Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Locus Cell Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Locus Cell Co., Ltd. Approves Establishment of Information Security Committee and Appoints First Committee Members	Dec. 27	CI
Locus Cell Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Locus Cell Co., Ltd.(TPEX:6891) added to S&P Global BMI Index	23-09-18	CI
Locus Cell Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Locus Cell Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Locus Cell Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-24	CI

Chart Locus Cell Co., Ltd.

Duration

Period

More charts

Company Profile

Locus Cell Co Ltd is a Taiwan-based company mainly engaged in the biotechnology and pharmaceutical business. The Company is currently expected to provide cell therapy contract manufacturing organization (CDMO) production and development services using a pilot Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) good manufacturing practices (GMP) facility, with related technologies for cell therapy products (expected to include tissue engineering related products, CAR-T, iPSCs, MSC and other cell therapy applications), process development and process scale-up, analytical method development and validation, clinical GMP manufacturing process for clinical trials, and stability testing.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LOCUS CELL CO., LTD.	+1.90%	198M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs